Summary of the technology
Predictive Kit to identify patients non responding to platinum therapy. 10 gene signature as a predictive biomarker for platinum treatment against different cancer types.
The invention consists in quantifying the expression of 10 genes from tumor cells to detect patients eligible for platinum treatment at higher risk of developing drug resistance and disease progression. Drugs such as cisplatin, oxaliplatin and carboplatin are used to treat various types of worldwide common cancer, but resistance is a frequent event. Patient stratification based on tumor gene expression profile allows to personalize treatment reducing side effects and costs.
Description of the technology
10 gene signature to discriminate responders and non responders patients to platinum therapy in different tumors.
i) Disease: Epithelial Ovarian Cancer, Triple Negative Breast Cancer and potentially applicable to other cancer treatable with platinum.
ii) Sample: mRNA extracted from cancer cells
iii) Technology: any technique to quantify nucleic acids.
i) Gene expression quantification can be performed with high throughput, widespread techniques
ii) Applicability in different tumor types treatable with platinum
iii) Reduction of treatment costs
iv) Improvement of patients life quality by avoiding ineffective treatment and potentially serious, useless side effects.
WHAT WE OFFER:
Deep knowledge in oncology field and biochemical techniques, cancer cell lines models, sample availability for in house test.
WHAT WE ARE LOOKING FOR:
Commercial partner interested in the development of the kit under license or co-development.
Intellectual property status
Patent already applied for
National Cancer Institute CRO Aviano
Additional information (attached documents)